Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Stock-for-stock merger of a public textile business
Represented a Special Committee of the Board of a public textile company in its consideration and consummation of a stock-for-stock merger with an more
Internal investigation involving an employee kickback scheme
Conducted internal investigation for a Fortune 100 company involving an employee kickback scheme. more
Products liability litigation for global automobile manufacturers
Defended global automobile manufacturers in over 30 lawsuits for wrongful death or personal injury arising from automobile accidents, including more
Internal investigation regarding potential Foreign Corrupt Practices Act violations
Internal investigation on behalf of a board of directors of a Fortune 500 company regarding potential Foreign Corrupt Practices Act more